Viridian Therapeutics Inc
LSE:0K1R
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Viridian Therapeutics Inc (0K1R) under the Base Case is USD per share.
Compared with the current market price of 30.41 USD, the stock appears .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What Viridian Therapeutics Does
Viridian Therapeutics is a biotechnology company that develops antibody medicines for serious autoimmune and rare diseases. Its main scientific focus is thyroid eye disease, a condition where the immune system attacks tissue around the eyes and can cause pain, swelling, and vision problems. The company is built around drug discovery and clinical development rather than drug manufacturing or retail sales.
- Headquarters
- United States of America US
- Employees
- 252
- IPO date
- Jun 18, 2014
Revenue & Expenses Breakdown
Viridian Therapeutics Inc
Earnings Waterfall
Viridian Therapeutics Inc
Continue 0K1R Research
Decided on Viridian Therapeutics? Get an email when 0K1R reaches the price you’d buy at. Free with an account.
Other Viridian Therapeutics listings
What is the Intrinsic Value of one 0K1R stock?
The intrinsic value for Viridian Therapeutics Inc (0K1R) under the Base Case is USD.
Is 0K1R stock undervalued or overvalued?
Compared with the current market price of 30.41 USD, the stock appears .
